Ignite Creation Date:
2024-05-06 @ 3:44 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04732013
Status:
UNKNOWN
Last Update Posted:
2022-04-21
First Post:
2020-11-27
Brief Title:
Noninvasive Chromosomal Screening for Embryo Selection Trial
Sponsor:
Olive Fertility Centre
Organization:
Olive Fertility Centre
Study Overview
Official Title:
Nonselection Pilot Study to Assess the Clinical Efficacy of Noninvasive Preimplantation Genetic Testing for Aneuploidy
Status:
UNKNOWN
Status Verified Date:
2022-04
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NICEST
Brief Summary:
To determine the diagnostic accuracy of non-invasive preimplantation genetic testing for aneuploidy NI-PGT-A for embryo selection
Detailed Description:
Hypothesis
Analysis of cell free DNA cfDNA released from developing embryos into spent culture media SCM can serve as a non-invasive method for performing preimplantation genetic testing for aneuploidy PGT-A A non-selection study that compares clinical outcomes to the NI-PGT-A results of the transferred embryos in a blinded fashion will characterize the diagnostic accuracy by determination of positive and negative predictive values
Justification
During the in vitro fertilization IVF process the selection of a healthy embryo is limited by the inability of the microscopic appearance to reveal the chromosomal complement Thus in order to reliably select chromosomally normal embryos preimplantation genetic testing for aneuploidy PGT-A is performed PGT-A requires biopsy of the embryo amplification of the DNA then next generation sequencing NGS to determine chromosome copy number
While the clinical utility of PGT-A has been demonstrated the process has limitations the most significant of which is the requirement for embryo biopsy Typically 5-10 cells are removed from the TE after the zona pellucida has been breached While the procedure can be safely and effectively performed by trained embryologists the obvious concern for damage to the embryo is relevant Even if implantation successfully occurs concern has been raised that biopsy of the embryo at this stage can lead to complications such as miscarriage or issues with placental function later in pregnancy Furthermore because the TE is destined to differentiate to placenta rather than the fetus itself there is controversy regarding if the chromosomal analysis of these cells is always representative of the chromosomal complement of the fetus For these reasons and because TE biopsy is laborious and expensive PGT-A has still not supplanted morphological evaluation as the clinical standard for embryo selection
An accurate noninvasive method for aneuploidy screening of embryos before implantation would be ideal To this end development of noninvasive PGT-A NI-PGT-A methods is an area of active investigation The approach leverages the ability to isolate cell-free DNA cfDNA that is secreted from the blastocyst into the spent culture media SCM SCM is routinely discarded after the embryo has been removed from culture however minute amounts of DNA from the embryo can be isolated amplified then sequenced for chromosomal copy number analysis The obvious advantage is that this process can occur without posing any harm to the embryo An additional putative benefit of this noninvasive approach is that the DNA is secreted from both the TE and the inner cell mass ICM theoretically serving as a more accurate representation of the fetal karyotype than the DNA isolated from just the TE biopsy alone
Technical limitations of deploying NI-PGT-A are related to the limited quantity of DNA available in the SCM Unlike other modes of genetic testing where ample amounts of genetic material is readily extracted from blood amniotic fluid or tissue biopsy cell-free DNA secretion from blastocysts is exceptionally minute in quantity However laboratory protocols are developing rapidly evidenced by numerous publications which have already demonstrated a high level of consistency when chromosomal copy number is analyzed by NI-PGT-A and traditional PGT-A in parallel
While these studies have illustrated proof of concept and preclinical validation the true diagnostic accuracy can only be assessed by evaluating the predictive value of negative euploid and positive aneuploid results Specifically embryos found to be euploid should have a greater ability for sustained implantation that proceeds to live birth while aneuploid embryos should have a dramatically lower rate of sustained implantation or will be predictive of clinical aneuploidy Without rigorous clinical validation using these results for embryo selection could lead to misdiagnosis causing selection of unhealthy embryos or selection against embryos that could have been potentially viable
To determine if NI-PGT-A is clinically robust we propose a non-selection pilot study whereby embryo selection is performed by routine clinical methods ie morphological selection However after the clinical outcome has manifested the SCM will be analyzed by a commercially available NI-PGT-A protocols in a blinded fashion By correlating clinical outcomes to NI-PGT-A results positive and negative predictive values can be calculated without bias Because no intervention will be performed that deviates from the clinical routine no additional risk will be posed to the embryo or parent
This study will serve as a pilot for a possible future trials If reasonable predictive value of NI-PGT-A is demonstrated a prospective selection study could be justified to investigate the utility of NI-PGT-A in a clinical setting
Research Design
Patients will undergo IVF-ICSI per clinical indication with plans to freeze all embryos for deferred embryo transfer Embryo culture will follow routine protocols and embryo selection for transfer will be performed using standard morphological criteria SCM from all blastocysts that appear viable will be collected and shipped to a reference lab Sequence 46 Specimens will be completely de-identified of patient information and labelled with an accession number NI-PGT-A analysis will be performed using a commercial kit according to manufacturers recommendations with technicians blinded to clinical outcomes When patients return for the embryo transfer cycle routine clinical protocol will be followed for endometrial preparation A single embryo will be selected according to routine morphological grading criteria and embryo transfer will be performed with standard techniques Initial pregnancy outcome will be documented with serum hCG testing If hCG testing is positive early pregnancy will be confirmed with ultrasound assessment per clinical routine After all patients have completed treatment and clinical outcomes manifested failed implantation miscarriage or ongoing pregnancy defined as viability beyond 13 weeks NI-PGT-A results will be released to the clinical team and correlated to clinical outcomes for calculation of predictive values All on-going pregnancies will be offered routine prenatal screening for fetal aneuploidies
Additional details regarding laboratory protocols are as follows
Blastocyst culture Embryo culture will follow routine protocols On day 3 post-fertilization embryos will be repeatedly pipetted through a series of culture media droplets in order to lower potential for maternal cell contamination Embryos will then be individually cultured in 35µL droplets of embryo culture medium to the blastocyst stage On day 5 or day 6 blastocyst development and quality will be evaluated using standard morphological criteria
Sample collection and blastocyst vitrification Blastocyst culture medium 20µL from selected embryos will be collected and transferred to PCR tubes and stored at -20C until whole genome amplification WGA Blastocysts will be frozen via routine vitrification protocol and stored in liquid nitrogen per routine clinical protocol Specimens will be completely de-identified of patient information and labelled with an accession number prior to shipping to reference lab Sequence46
Whole genome amplification and DNA sequencing NI-PGT-A analysis will be performed upon receipt using a commercial kit according to manufacturers recommendations with technicians blinded to clinical outcomes DNA will be amplified by whole genome amplification WGA and barcoded to prepare libraries The libraries are then loaded onto an Ion Chef instrument for template preparation by automated clonal amplification and then loaded onto a chip for DNA sequencing on an Ion Genestudio S5 Prime system with approximately 150000-200000 sequencing reads per sample Data is analyzed using the Ion Reporter software v510 or later Ploidy will be measured using baseline Ion ReproSeq Low-Coverage Whole-Genome 99M Baseline Standard quality control measures will be evaluated Results will be released to the clinical team 6 weeks post-embryo transfer and correlated to clinical outcomes for calculation of predictive values
Patient population
Inclusion Criteria
Patient undergoing IVF-ICSI 21 - 35 years old at the time of enrollment Elective freeze-all cycle Planning for single embryo transfer
Exclusion Criteria
Undergoing PGT-A PGT-SR PGT-M History of recurrent pregnancy loss History of recurrent implantation failure Planning on transfer of more than 1 embryo
The justification for the age category is to control for age-related factors other than aneuploidy that may influence implantation so variables that could compound predictive value calculations are minimized Limiting participation to patients under 35 also optimizes embryo selection such that morphologically normal embryos are most likely healthy Furthermore patients in this age category have the lowest risk for clinical aneuploidies such as Down syndrome
Data management and storage
Research samples will be identified by a unique accession number but no patient identifying information The samples will be processed by Sequence46 with results associated with the accession number The data will be uploaded via a secure cloud service which will be accessed by the primary investigator to merge with the electronic case report form eCRF that will be stored locally at the Olive Fertility Centre on an encrypted hard drive that will be backed-up on a secondary local drive The eCRF will contain the patients unique medical record number and age but will not document name birthdate or any other identifying information Results of the NI-PGT-A analysis and clinical outcome will also be stored in the eCRF
Research data will be retained for 5 years after the date of publication
Statistical analysis
Diagnostic accuracy will be interpreted in the context of positive and negative predictive values
A positive result is a finding consistent with aneuploidy or mosaicism A negative result is a finding consistent with euploidy
PPV Failed implantation miscarriage clinical aneuploidy All Positive Results NPV Ongoing pregnancy All Negative Results
Sample size calculation
One hundred-twenty 120 patients should suffice for this pilot study Previous research has established that in patients aged 35 or younger the ratio of euploidaneuploid embryos is approximately 6040 Of euploid embryos approximately 70 will implant of which 85 should continue to viability Of aneuploid embryos approximately 25 will implant of which 99 will miscarry the risk of a clinical aneuploidy is less than 05 in women 35 and under
Given these probabilities of the 120 patients to be enrolled 72 euploid embryos are expected of which 50 should implant and 43 will continue as ongoing viable pregnancies Of the 48 that are expected to be aneuploid 12 will implant of which all should miscarry the chance for a clinical aneuploidy in this population is less than 05
Recruitment
Patients who are pursuing IVF-ICSI at the Olive Fertility Centre and meet inclusionexclusion criteria will be recruited directly by the co-investigators Flyers will be posted within the clinic
Analysis of cell free DNA cfDNA released from developing embryos into spent culture media SCM can serve as a non-invasive method for performing preimplantation genetic testing for aneuploidy PGT-A A non-selection study that compares clinical outcomes to the NI-PGT-A results of the transferred embryos in a blinded fashion will characterize the diagnostic accuracy by determination of positive and negative predictive values
Justification
During the in vitro fertilization IVF process the selection of a healthy embryo is limited by the inability of the microscopic appearance to reveal the chromosomal complement Thus in order to reliably select chromosomally normal embryos preimplantation genetic testing for aneuploidy PGT-A is performed PGT-A requires biopsy of the embryo amplification of the DNA then next generation sequencing NGS to determine chromosome copy number
While the clinical utility of PGT-A has been demonstrated the process has limitations the most significant of which is the requirement for embryo biopsy Typically 5-10 cells are removed from the TE after the zona pellucida has been breached While the procedure can be safely and effectively performed by trained embryologists the obvious concern for damage to the embryo is relevant Even if implantation successfully occurs concern has been raised that biopsy of the embryo at this stage can lead to complications such as miscarriage or issues with placental function later in pregnancy Furthermore because the TE is destined to differentiate to placenta rather than the fetus itself there is controversy regarding if the chromosomal analysis of these cells is always representative of the chromosomal complement of the fetus For these reasons and because TE biopsy is laborious and expensive PGT-A has still not supplanted morphological evaluation as the clinical standard for embryo selection
An accurate noninvasive method for aneuploidy screening of embryos before implantation would be ideal To this end development of noninvasive PGT-A NI-PGT-A methods is an area of active investigation The approach leverages the ability to isolate cell-free DNA cfDNA that is secreted from the blastocyst into the spent culture media SCM SCM is routinely discarded after the embryo has been removed from culture however minute amounts of DNA from the embryo can be isolated amplified then sequenced for chromosomal copy number analysis The obvious advantage is that this process can occur without posing any harm to the embryo An additional putative benefit of this noninvasive approach is that the DNA is secreted from both the TE and the inner cell mass ICM theoretically serving as a more accurate representation of the fetal karyotype than the DNA isolated from just the TE biopsy alone
Technical limitations of deploying NI-PGT-A are related to the limited quantity of DNA available in the SCM Unlike other modes of genetic testing where ample amounts of genetic material is readily extracted from blood amniotic fluid or tissue biopsy cell-free DNA secretion from blastocysts is exceptionally minute in quantity However laboratory protocols are developing rapidly evidenced by numerous publications which have already demonstrated a high level of consistency when chromosomal copy number is analyzed by NI-PGT-A and traditional PGT-A in parallel
While these studies have illustrated proof of concept and preclinical validation the true diagnostic accuracy can only be assessed by evaluating the predictive value of negative euploid and positive aneuploid results Specifically embryos found to be euploid should have a greater ability for sustained implantation that proceeds to live birth while aneuploid embryos should have a dramatically lower rate of sustained implantation or will be predictive of clinical aneuploidy Without rigorous clinical validation using these results for embryo selection could lead to misdiagnosis causing selection of unhealthy embryos or selection against embryos that could have been potentially viable
To determine if NI-PGT-A is clinically robust we propose a non-selection pilot study whereby embryo selection is performed by routine clinical methods ie morphological selection However after the clinical outcome has manifested the SCM will be analyzed by a commercially available NI-PGT-A protocols in a blinded fashion By correlating clinical outcomes to NI-PGT-A results positive and negative predictive values can be calculated without bias Because no intervention will be performed that deviates from the clinical routine no additional risk will be posed to the embryo or parent
This study will serve as a pilot for a possible future trials If reasonable predictive value of NI-PGT-A is demonstrated a prospective selection study could be justified to investigate the utility of NI-PGT-A in a clinical setting
Research Design
Patients will undergo IVF-ICSI per clinical indication with plans to freeze all embryos for deferred embryo transfer Embryo culture will follow routine protocols and embryo selection for transfer will be performed using standard morphological criteria SCM from all blastocysts that appear viable will be collected and shipped to a reference lab Sequence 46 Specimens will be completely de-identified of patient information and labelled with an accession number NI-PGT-A analysis will be performed using a commercial kit according to manufacturers recommendations with technicians blinded to clinical outcomes When patients return for the embryo transfer cycle routine clinical protocol will be followed for endometrial preparation A single embryo will be selected according to routine morphological grading criteria and embryo transfer will be performed with standard techniques Initial pregnancy outcome will be documented with serum hCG testing If hCG testing is positive early pregnancy will be confirmed with ultrasound assessment per clinical routine After all patients have completed treatment and clinical outcomes manifested failed implantation miscarriage or ongoing pregnancy defined as viability beyond 13 weeks NI-PGT-A results will be released to the clinical team and correlated to clinical outcomes for calculation of predictive values All on-going pregnancies will be offered routine prenatal screening for fetal aneuploidies
Additional details regarding laboratory protocols are as follows
Blastocyst culture Embryo culture will follow routine protocols On day 3 post-fertilization embryos will be repeatedly pipetted through a series of culture media droplets in order to lower potential for maternal cell contamination Embryos will then be individually cultured in 35µL droplets of embryo culture medium to the blastocyst stage On day 5 or day 6 blastocyst development and quality will be evaluated using standard morphological criteria
Sample collection and blastocyst vitrification Blastocyst culture medium 20µL from selected embryos will be collected and transferred to PCR tubes and stored at -20C until whole genome amplification WGA Blastocysts will be frozen via routine vitrification protocol and stored in liquid nitrogen per routine clinical protocol Specimens will be completely de-identified of patient information and labelled with an accession number prior to shipping to reference lab Sequence46
Whole genome amplification and DNA sequencing NI-PGT-A analysis will be performed upon receipt using a commercial kit according to manufacturers recommendations with technicians blinded to clinical outcomes DNA will be amplified by whole genome amplification WGA and barcoded to prepare libraries The libraries are then loaded onto an Ion Chef instrument for template preparation by automated clonal amplification and then loaded onto a chip for DNA sequencing on an Ion Genestudio S5 Prime system with approximately 150000-200000 sequencing reads per sample Data is analyzed using the Ion Reporter software v510 or later Ploidy will be measured using baseline Ion ReproSeq Low-Coverage Whole-Genome 99M Baseline Standard quality control measures will be evaluated Results will be released to the clinical team 6 weeks post-embryo transfer and correlated to clinical outcomes for calculation of predictive values
Patient population
Inclusion Criteria
Patient undergoing IVF-ICSI 21 - 35 years old at the time of enrollment Elective freeze-all cycle Planning for single embryo transfer
Exclusion Criteria
Undergoing PGT-A PGT-SR PGT-M History of recurrent pregnancy loss History of recurrent implantation failure Planning on transfer of more than 1 embryo
The justification for the age category is to control for age-related factors other than aneuploidy that may influence implantation so variables that could compound predictive value calculations are minimized Limiting participation to patients under 35 also optimizes embryo selection such that morphologically normal embryos are most likely healthy Furthermore patients in this age category have the lowest risk for clinical aneuploidies such as Down syndrome
Data management and storage
Research samples will be identified by a unique accession number but no patient identifying information The samples will be processed by Sequence46 with results associated with the accession number The data will be uploaded via a secure cloud service which will be accessed by the primary investigator to merge with the electronic case report form eCRF that will be stored locally at the Olive Fertility Centre on an encrypted hard drive that will be backed-up on a secondary local drive The eCRF will contain the patients unique medical record number and age but will not document name birthdate or any other identifying information Results of the NI-PGT-A analysis and clinical outcome will also be stored in the eCRF
Research data will be retained for 5 years after the date of publication
Statistical analysis
Diagnostic accuracy will be interpreted in the context of positive and negative predictive values
A positive result is a finding consistent with aneuploidy or mosaicism A negative result is a finding consistent with euploidy
PPV Failed implantation miscarriage clinical aneuploidy All Positive Results NPV Ongoing pregnancy All Negative Results
Sample size calculation
One hundred-twenty 120 patients should suffice for this pilot study Previous research has established that in patients aged 35 or younger the ratio of euploidaneuploid embryos is approximately 6040 Of euploid embryos approximately 70 will implant of which 85 should continue to viability Of aneuploid embryos approximately 25 will implant of which 99 will miscarry the risk of a clinical aneuploidy is less than 05 in women 35 and under
Given these probabilities of the 120 patients to be enrolled 72 euploid embryos are expected of which 50 should implant and 43 will continue as ongoing viable pregnancies Of the 48 that are expected to be aneuploid 12 will implant of which all should miscarry the chance for a clinical aneuploidy in this population is less than 05
Recruitment
Patients who are pursuing IVF-ICSI at the Olive Fertility Centre and meet inclusionexclusion criteria will be recruited directly by the co-investigators Flyers will be posted within the clinic
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None